10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2010
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 0-27206
Astrotech Corporation
(Exact name of registrant as specified in this charter)
|
|
|
Washington
(State or other jurisdiction
of incorporation or organization)
|
|
91-1273737
(I.R.S. Employer
Identification No.) |
401 Congress Avenue, Suite 1650
Austin, Texas 78701
(Address of principal executive offices and zip code)
(512) 485-9530
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files). Yes o
No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See definition of large accelerated filer,
accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer o
|
|
Non-accelerated filer o
(Do not check if a smaller reporting company)
|
|
Smaller reporting company þ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act.) Yes o No þ
As of May 11, 2010 there were 19,137,406 shares of the registrants common stock outstanding.
ASTROTECH CORPORATION AND SUBSIDIARIES
QUARTERLY REPORT ON FORM 10-Q
TABLE OF CONTENTS
1
PART I: FINANCIAL INFORMATION
ITEM 1. Condensed Consolidated Financial Statements
ASTROTECH CORPORATION AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
June 30, |
|
|
|
2010 |
|
|
2009 |
|
|
|
(unaudited) |
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
6,253 |
|
|
$ |
4,730 |
|
Accounts receivable, net |
|
|
8,270 |
|
|
|
12,279 |
|
Short-term note receivable, net |
|
|
675 |
|
|
|
|
|
Prepaid expenses and other current assets |
|
|
955 |
|
|
|
591 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
16,153 |
|
|
|
17,600 |
|
|
|
|
|
|
|
|
Property & equipment, net |
|
|
39,972 |
|
|
|
40,226 |
|
Other assets, net |
|
|
34 |
|
|
|
402 |
|
Long-term note receivable, net |
|
|
|
|
|
|
691 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
56,159 |
|
|
$ |
58,919 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders Equity |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
650 |
|
|
$ |
2,965 |
|
Accrued liabilities and other |
|
|
2,161 |
|
|
|
2,356 |
|
Deferred revenue |
|
|
1,271 |
|
|
|
3,594 |
|
Term note payable |
|
|
3,415 |
|
|
|
267 |
|
Senior convertible notes payable- 5.5% |
|
|
5,111 |
|
|
|
|
|
Other |
|
|
72 |
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
12,680 |
|
|
|
9,182 |
|
|
|
|
|
|
|
|
Deferred revenue |
|
|
598 |
|
|
|
649 |
|
Term note payable, net of current portion |
|
|
|
|
|
|
3,324 |
|
Senior convertible notes payable- 5.5% |
|
|
|
|
|
|
5,111 |
|
Other |
|
|
|
|
|
|
105 |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
13,278 |
|
|
|
18,371 |
|
|
|
|
|
|
|
|
Stockholders Equity |
|
|
|
|
|
|
|
|
Preferred stock, no par value, convertible,
2,500,000 authorized
shares, 0 issued and
outstanding shares, at March 31, 2010 and
June 30, 2009 |
|
|
|
|
|
|
|
|
Common
stock, no par value, 75,000,000 shares
authorized 16,953,511 and 16,754,378
shares issued at March 31, 2010 and June 30,
2009, respectively |
|
|
183,459 |
|
|
|
183,341 |
|
Treasury stock, 311,660 shares at cost |
|
|
(237 |
) |
|
|
(237 |
) |
Additional paid-in capital |
|
|
934 |
|
|
|
1,663 |
|
Retained deficit |
|
|
(142,388 |
) |
|
|
(144,219 |
) |
Noncontrolling Interest |
|
|
1,113 |
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity |
|
|
42,881 |
|
|
|
40,548 |
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
56,159 |
|
|
$ |
58,919 |
|
|
|
|
|
|
|
|
See accompanying notes to unaudited condensed consolidated financial statements.
2
ASTROTECH CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
March 31, |
|
|
March 31, |
|
|
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
|
(unaudited) |
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
$ |
6,647 |
|
|
$ |
11,849 |
|
|
$ |
22,489 |
|
|
$ |
21,608 |
|
Costs of revenue |
|
|
3,360 |
|
|
|
4,825 |
|
|
|
8,962 |
|
|
|
11,593 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
3,287 |
|
|
|
7,024 |
|
|
|
13,527 |
|
|
|
10,015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
3,170 |
|
|
|
2,671 |
|
|
|
9,515 |
|
|
|
6,520 |
|
Research and development |
|
|
1,117 |
|
|
|
553 |
|
|
|
2,119 |
|
|
|
1,636 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
4,287 |
|
|
|
3,224 |
|
|
|
11,634 |
|
|
|
8,156 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations |
|
|
(1,000 |
) |
|
|
3,800 |
|
|
|
1,893 |
|
|
|
1,859 |
|
Gain on notes repurchased |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
665 |
|
Interest and other expense, net |
|
|
(26 |
) |
|
|
(105 |
) |
|
|
(366 |
) |
|
|
(329 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
|
|
(1,026 |
) |
|
|
3,695 |
|
|
|
1,527 |
|
|
|
2,195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense |
|
|
53 |
|
|
|
(93 |
) |
|
|
(22 |
) |
|
|
(93 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
(973 |
) |
|
|
3,602 |
|
|
|
1,505 |
|
|
|
2,102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: Net loss
attributable to noncontrolling interest |
|
|
(326 |
) |
|
|
|
|
|
|
(326 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Astrotech
Corporation |
|
$ |
(647 |
) |
|
$ |
3,602 |
|
|
$ |
1,831 |
|
|
$ |
2,102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share-basic |
|
$ |
(0.04 |
) |
|
$ |
0.22 |
|
|
$ |
0.11 |
|
|
$ |
0.13 |
|
Weighted average common shares outstanding,
basic |
|
|
16,610 |
|
|
|
16,547 |
|
|
|
16,531 |
|
|
|
16,444 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share, diluted |
|
$ |
(0.04 |
) |
|
$ |
0.21 |
|
|
$ |
0.10 |
|
|
$ |
0.12 |
|
Weighted average common shares outstanding,
diluted |
|
|
16,610 |
|
|
|
17,316 |
|
|
|
18,278 |
|
|
|
16,867 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to unaudited condensed consolidated financial statements.
3
ASTROTECH CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
March 31, |
|
|
|
2010 |
|
|
2009 |
|
|
|
(unaudited) |
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|
Net income |
|
$ |
1,505 |
|
|
$ |
2,102 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
753 |
|
|
|
251 |
|
Depreciation and amortization |
|
|
1,601 |
|
|
|
1,687 |
|
Gain on note repurchase |
|
|
|
|
|
|
(665 |
) |
Other |
|
|
|
|
|
|
27 |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
4,009 |
|
|
|
(5,530 |
) |
Deferred revenue |
|
|
(2,374 |
) |
|
|
1,673 |
|
Accounts payable |
|
|
(2,315 |
) |
|
|
(859 |
) |
Advances for construction contract |
|
|
|
|
|
|
(4,568 |
) |
Restricted cash |
|
|
|
|
|
|
5,162 |
|
Other assets and liabilities |
|
|
(184 |
) |
|
|
723 |
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
2,995 |
|
|
|
3 |
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Purchases of property, equipment and leasehold improvements |
|
|
(1,347 |
) |
|
|
(538 |
) |
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(1,347 |
) |
|
|
(538 |
) |
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock |
|
|
75 |
|
|
|
|
|
Proceeds received from revolving credit facility, net of prepayments |
|
|
|
|
|
|
550 |
|
Repurchase of Treasury Stock |
|
|
|
|
|
|
(120 |
) |
Term loan payment |
|
|
(200 |
) |
|
|
(200 |
) |
Repurchase of notes |
|
|
|
|
|
|
(1,085 |
) |
|
|
|
|
|
|
|
Net cash used in financing activities |
|
|
(125 |
) |
|
|
(855 |
) |
|
|
|
|
|
|
|
Net change in cash and cash equivalents |
|
|
1,523 |
|
|
|
(1,390 |
) |
Cash and cash equivalents at beginning of period |
|
|
4,730 |
|
|
|
2,640 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
6,253 |
|
|
$ |
1,250 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of cash flow information: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest |
|
$ |
278 |
|
|
$ |
388 |
|
|
|
|
|
|
|
|
Cash paid for income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to unaudited condensed consolidated financial statements.
4
ASTROTECH CORPORATION AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements
1. Description of the Company and Operating Environment
Astrotech Corporation (Nasdaq: ASTC) (Astrotech, the Company, we, us or our) is a
commercial aerospace company that provides spacecraft payload processing and government services,
designs and manufactures space hardware, and develops space technologies for use on Earth.
Astrotech has experience supporting both manned and unmanned missions to space with product and
service support including space hardware design and manufacturing, research and logistics
expertise, engineering and support services, and payload processing and integration. Through new
business initiatives such as 1st Detect and Astrogenetix, Astrotech is paving the way in the
commercialization of space by translating space-based technology into terrestrial applications.
Our Business Units
Astrotech Space Operations, Inc. (ASO) ASO is the leading commercial supplier of satellite
launch processing services in the United States. ASO provides processing support for government and
commercial customers for their complex communication, Earth observation and deep space satellites.
ASOs spacecraft processing facilities are among the elite in the industry, with more than 300,000
square feet of space that can support the largest, five-meter class satellites. ASO has provided
launch processing support for government and commercial customers for nearly a quarter century,
successfully processing more than 280 spacecraft. ASOs turn-key approach to the total satellite
life cycle leverages the Companys legacy in ground processing operations, and engineering and
support services. By offering the satellite customer mission design and planning, ground and launch
operations, and mission operations and end-user enhancement, ASO provides End-to-End Mission
Assurance for its customers. This includes assistance with mission design, regulatory planning,
preliminary engineering and more detailed systems, mechanical, software, electrical, and optical
engineering services.
Spacetech Our other business unit is an incubator intended to develop space-industry technologies
into commercial applications to be sold to consumers and industry. Spacetech has developed three
business initiatives to date: 1st Detect Corporation (1st Detect), Astrogenetix Inc.
(Astrogenetix) and AirWard Corporation (Airward). 1st Detect Corporations business began under
a Space Act Agreement with the National Aeronautics and Space Administration (NASA) for a
chemical detection unit to be used on the International Space Station. 1st Detect engineers have
developed a Miniature Chemical Detector, a device in the mass spectrometer market that we believe
will fill a niche by being highly accurate, lightweight, battery-powered, durable and inexpensive.
Astrogenetix is a development-stage biotechnology company created to use the unique environment of
space to develop novel therapeutic products. A natural extension of the many years of experience
preparing, launching, and operating over 1,500 science payloads in space, Astrogenetix is in the
process of developing products from microgravity discoveries. AirWard designed and manufactured
shipping containers to transport oxygen bottles and oxygen generators for commercial aircraft.
Further investment in Airward was suspended in the period ended March 31, 2010, as
the initiative has not yielded the anticipated return for shareholders.
2. Basis of Presentation
In the opinion of Astrotech management, the accompanying unaudited condensed consolidated financial
statements reflect all adjustments (consisting of normal recurring accruals) necessary for a fair
presentation of the Companys interim financial statements.
The results of operations for the three and nine months ended March 31, 2010 are not necessarily
indicative of full year results. Our results of operations typically fluctuate significantly from
quarter to quarter. The interim unaudited condensed consolidated financial statements should be
read in conjunction with our audited consolidated financial statements included in our 2009 Annual
Report on Form 10-K, as amended (the 2009 10-K).
Certain amounts reported in previous periods have been reclassified to conform to the current
period presentation.
5
3. Noncontrolling Interest
In January 2010, restricted shares of Astrotech subsidiaries, 1st Detect and Astrogenetix, were
granted to certain employees, directors and officers, resulting in Astrotech owning less than 100%
of the subsidiaries. The Company applied non-controlling interest accounting for the period ended
March 31, 2010, which requires us to clearly identify the non-controlling interest in the balance
sheets and income statements. We disclose three measures of net income: net income, net income
attributable to noncontrolling interest, and net income attributable to Astrotech Corporation. Our
operating cash flows in our consolidated statements of cash flows reflect net income, while our
basic and diluted earnings per share calculations reflect net income attributable to Astrotech
Corporation.
Noncontrolling Interest
|
|
|
|
|
Beginning balance at July 1, 2009 |
|
$ |
|
|
Net loss attributable to noncontrolling interest |
|
|
(326 |
) |
Distributions of restricted stock |
|
|
1,439 |
|
|
|
|
|
Ending balance at March 31, 2010 |
|
$ |
1,113 |
|
|
|
|
|
As of March 31, 2010 the Companys share of income and losses is 86% for 1st Detect and 79% for
Astrogenetix.
4. Net Income (loss) per Share
Basic net income (loss) per share is computed on the basis of the weighted average number of shares
of common stock outstanding during the period. Diluted net income (loss) per share is computed on
the basis of the weighted average number of shares of common stock plus the effect of dilutive
potential common shares outstanding during the period using the treasury stock method and the
if-converted method. Dilutive potential common shares include outstanding stock options,
convertible debt, and shared-based awards. The reconciliation and the components of basic and
diluted net income (loss) per share are as follows (in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
March 31, |
|
|
March 31, |
|
|
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss), basic and diluted |
|
$ |
(647 |
) |
|
$ |
3,602 |
|
|
$ |
1,831 |
|
|
$ |
2,102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for basic net income
(loss) per share weighted
average common stock outstanding |
|
|
16,610 |
|
|
|
16,547 |
|
|
|
16,531 |
|
|
|
16,444 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilutive common stock
equivalents common stock options
and share-based awards |
|
|
|
|
|
|
769 |
|
|
|
1,747 |
|
|
|
423 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for diluted
net income (loss) per share
weighted average common stock
outstanding and dilutive common
stock equivalents |
|
|
16,610 |
|
|
|
17,316 |
|
|
|
18,278 |
|
|
|
16,867 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income (loss) per share |
|
$ |
(0.04 |
) |
|
$ |
0.22 |
|
|
$ |
0.11 |
|
|
$ |
0.13 |
|
Diluted net income (loss) per share |
|
$ |
(0.04 |
) |
|
$ |
0.21 |
|
|
$ |
0.10 |
|
|
$ |
0.12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The senior convertible notes payable outstanding for the three and nine months ended March
31, 2010 and 2009, which are convertible into 340,904 shares of common stock at $15.00 per share,
have not been included in the computation of diluted net income (loss) per share as the impact to
net income (loss) per share is anti-dilutive.
Options to purchase 40,900 shares of common stock at exercise prices ranging from $4.40 to $48.75
per share outstanding for the three and nine months ended March 31, 2010, were not included in
diluted net income (loss) per share, as the impact to net income (loss) per share is anti-dilutive.
Options to purchase 1,217,891 and 1,182,891 shares of common stock at exercise prices ranging from $0.30 to $51.25 per share outstanding for
the three and nine months ended March 31, 2009, respectively, were not included in diluted net
income (loss) per share, as the impact to net income (loss) per share is anti-dilutive.
6
5. Revenue Recognition
Astrotech recognizes revenue employing several generally accepted revenue recognition methodologies
across its business units. The methodology used is based on contract type and the manner in which
products and services are provided.
Revenue generated by Astrotechs payload processing facilities is recognized ratably over the
occupancy period of the satellite while in the Astrotech facilities. For the multi-year
guaranteed-mission contract with United Launch Alliance, revenue is billed and recognized on a
quarterly basis. The percentage-of-completion method is used for all contracts where incurred costs
can be reasonably estimated and successful completion can be reasonably assured at inception.
Changes in estimated costs to complete and provisions for contract losses are recognized in the
period they become known. Revenue for the sale of commercial products is recognized at shipment.
A Summary of Revenue Recognition Methods
|
|
|
|
|
Services/Products Provided |
|
Contract Type |
|
Method of Revenue Recognition |
|
Payload Processing Facilities
|
|
Firm Fixed Price Mission
Specific
|
|
Ratably, over the occupancy
period of a satellite within
the facility from arrival
through launch |
|
|
|
|
|
|
|
Firm Fixed Price
Guaranteed Number of
Missions
|
|
For multi-year contract
payments recognized ratably
over the contract period |
|
|
|
|
|
Commercial Space Habitat
Modules, Integration &
Operations Support Services
and Construction contracts
|
|
Firm Fixed Price
|
|
Percentage-of-completion
based on costs incurred |
|
|
|
|
|
Configuration Management,
Engineering Services
|
|
Cost Reimbursable
Award/Fixed Fee
|
|
Reimbursable costs incurred
plus award/fixed fee |
|
|
|
|
|
Commercial Products
|
|
Specific Purchase Order Based
|
|
At shipment |
Under certain contracts, we make expenditures for specific enhancements and/or additions to our
facilities where the customer agrees to pay a fixed fee to deliver the enhancement or addition. We
account for such agreements as a reduction in the cost of such investments and recognize any excess
of amounts collected above the expenditure as revenue. Revenue for ASO recognized under a building
modification contract with a government agency was accounted for under the percentage-of-completion
method based on costs incurred over the period of the agreement.
6. Debt
Credit Facilities
In February 2008, we entered into a financing facility with a bank providing a $4.0 million term
loan maturing February 2011. In March 2010, the Company secured a $2.0 million revolving credit
facility, terminating in February 2011, by completing the third amendment to the original loan
agreement dated February 6, 2008. The term loan requires monthly payments of principal plus
interest at the rate of prime plus 1.75%, and the revolving credit facility incurs interest at the
rate of prime plus 0.75%, but not less than 5.0%. The bank financing facilities are secured by the
assets of ASO, including accounts receivable, and require us to comply with designated covenants.
The balance of the $4.0 million term loan at March 31, 2010 was $3.4 million. There was no
outstanding balance on the revolving credit facility at March 31, 2010.
Senior Convertible Notes
At March 31, 2010, Astrotech had $5.1 million of senior convertible notes outstanding which mature
on October 15, 2010 and pay interest semi-annually on April 15 and October 15.
7
7. Fair Value Measurement
In general, fair values utilize quoted prices in active (when available) markets for identical
assets or liabilities. The following table presents the carrying amounts and estimated fair values
of certain of the Companys financial instruments as of March 31, 2010 and June 30, 2009, (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2010 |
|
|
June 30, 2009 |
|
|
|
Carrying |
|
|
Fair |
|
|
Carrying |
|
|
Fair |
|
|
|
Amount |
|
|
Value |
|
|
Amount |
|
|
Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term loan payable |
|
$ |
3,415 |
|
|
$ |
3,415 |
|
|
$ |
3,591 |
|
|
$ |
3,591 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior convertible notes payable 5.5% |
|
$ |
5,111 |
|
|
$ |
2,658 |
|
|
$ |
5,111 |
|
|
$ |
2,650 |
|
The fair value of our long-term debt is estimated based on the current rates offered for
similar financial instruments. The carrying amounts of cash and cash equivalents, accounts
receivable, notes receivable, and accounts payable approximate their fair market value due to the
relatively short duration of these instruments.
In April 2009, the FASB issued guidance changing fair value accounting. This pronouncement requires
disclosures about fair value of financial instruments in interim financial statements as well as in
annual financial statements and requires those disclosures in summarized financial information in
interim financial statements. We adopted this guidance on July 1, 2009 and the adoption of these
changes had no impact on the consolidated financial statements.
8. Business and Credit Risk Concentration
A substantial portion of our revenue has been generated under contracts with the U.S. Government.
During the nine months ended March 31, 2010 and 2009, approximately 53% and 57%, respectively, of
our revenues were generated under U.S. Government contracts. Accounts receivable totaled $8.3
million at March 31, 2010, of which, 50% is attributed to the U.S. Government.
The Company maintains funds in bank accounts that may exceed the limit insured by the Federal
Deposit Insurance Corporation, or FDIC. In October 2008, the FDIC increased its insurance to
$250,000 per depositor, and to an unlimited amount for non-interest bearing accounts. The risk of
loss attributable to these uninsured balances is mitigated by depositing funds in what we believe
to be high credit quality financial institutions. The Company has not experienced any losses in
such accounts.
9. Segment Information
Managements primary financial and operating reviews focus on ASO, the core business unit. All
intercompany transactions between business units have been eliminated in consolidation.
Key financial metrics for the three months ended March 31, 2010 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Three Months Ended |
|
|
|
March 31, 2010 |
|
|
March 31, 2009 |
|
|
|
|
|
|
|
Income (loss) |
|
|
|
|
|
|
Income (loss) |
|
Revenue and Income (loss) |
|
|
|
|
|
before |
|
|
|
|
|
|
before |
|
(in thousands) |
|
Revenue |
|
|
income taxes |
|
|
Revenue |
|
|
income taxes |
|
ASO |
|
$ |
6,647 |
|
|
$ |
867 |
|
|
$ |
11,604 |
|
|
$ |
6,706 |
|
Spacetech |
|
|
|
|
|
|
(1,893 |
) |
|
|
245 |
|
|
|
(3,011 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
6,647 |
|
|
$ |
(1,026 |
) |
|
$ |
11,849 |
|
|
$ |
3,695 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8
Key financial metrics for the nine months ended March 31, 2010 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
Nine Months Ended |
|
|
|
March 31, 2010 |
|
|
March 31, 2009 |
|
|
|
|
|
|
|
Income (loss) |
|
|
|
|
|
|
Income (loss) |
|
Revenue and Income (loss) |
|
|
|
|
|
before |
|
|
|
|
|
|
before |
|
(in thousands) |
|
Revenue |
|
|
income taxes |
|
|
Revenue |
|
|
income taxes |
|
ASO |
|
$ |
22,489 |
|
|
$ |
6,546 |
|
|
$ |
21,003 |
|
|
$ |
9,671 |
|
Spacetech |
|
|
|
|
|
|
(5,019 |
) |
|
|
605 |
|
|
|
(7,476 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
22,489 |
|
|
$ |
1,527 |
|
|
$ |
21,608 |
|
|
$ |
2,195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2010 |
|
|
June 30, 2009 |
|
Assets |
|
Fixed |
|
|
Total |
|
|
Fixed |
|
|
Total |
|
(in thousands) |
|
Assets, net |
|
|
Assets |
|
|
Assets, net |
|
|
Assets |
|
ASO |
|
$ |
39,749 |
|
|
$ |
51,496 |
|
|
$ |
39,815 |
|
|
$ |
52,595 |
|
Spacetech |
|
|
223 |
|
|
|
4,663 |
|
|
|
411 |
|
|
|
6,324 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
39,972 |
|
|
$ |
56,159 |
|
|
$ |
40,226 |
|
|
$ |
58,919 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10. Equity and Other Long Term Incentive Plans
As of March 31, 2010, 61,785 shares of Common Stock were reserved for future grants under the 2008
Stock Incentive Plan. In the nine months ended March 31, 2010 and 2009, we recognized compensation
expense of $0.6 million and $0.2 million, respectively, for restricted stock and stock options
outstanding.
On January 19, 2010, an independent committee of the board of directors of 1st Detect,
a subsidiary of the Company,
approved a grant of 1,180 restricted stock shares and 1,820 stock purchase warrants to certain
officers, directors and employees of 1st Detect. The awards vest 50% a year over a 2
year period. We recognized compensation expense of $25,000 for restricted stock and warrants
outstanding in 2010. The Company utilized the Black-Scholes
methodology in determining the fair market value of the warrants of
$7,000 of which $1,000 was recognized in 2010.
The
foregoing description is a summary and is qualified in its entirety by
reference to the form of the Restricted Stock Agreement, which is
filed as Exhibit 10.1 hereto and is incorporated by reference, and
the form of the Stock Purchase Warrant, which is filed as Exhibit
10.2 hereto and is incorporated by reference.
On January 19, 2010, an independent
committee of the board of directors of Astrogenetix, a subsidiary of the Company, approved a grant of 1,550 restricted stock shares
and 2,050 stock purchase warrants to certain officers, directors and employees of Astrogenetix.
The awards vest 50% a year over a 2 year period. We recognized compensation expense of $32,000 for
restricted stock and warrants outstanding in 2010. The Company
utilized the Black-Scholes methodology in determining the fair market
value of the warrants of $6,000 of which $1,000 was recognized in
2010.
The
foregoing description is a summary and is qualified in its entirety by
reference to the form of the Restricted Stock Agreement, which is
filed as Exhibit 10.3 hereto and is incorporated by reference, and
the form of the Stock Purchase Warrant, which is filed as Exhibit
10.4 hereto and is incorporated by reference.
Equity Grants
In the first and second quarters of fiscal 2010, the Compensation Committee of the Board of
Directors granted directors, named executive officers and employees 1,995,559 and 410,000,
respectively, of restricted shares in recognition of the positive fiscal 2009 financial and
operating performance. The shares were issued from the 2008 Stock Incentive Plan, vest 33.33% a
year over a three year period and expire upon employee termination.
Stock Options
There were no options granted in the nine months ended March 31, 2010. Compensation costs
recognized related to vested stock option awards during this time was $1,000. At March 31,
2010 and 2009, there was $0.1 million
and $0.2 million, respectively, of total unrecognized compensation cost related to non-vested stock
options, which is expected to be recognized over a weighted average period of 2.5 years.
9
The Companys stock options activity for the three months ended March 31, 2010 was as follows:
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Weighted Average |
|
|
|
(in thousands) |
|
|
Exercise Price |
|
Outstanding at December 31, 2009 |
|
|
971 |
|
|
$ |
1.25 |
|
|
|
|
|
|
|
|
Granted |
|
|
|
|
|
|
|
|
Exercised |
|
|
(63 |
) |
|
|
0.45 |
|
Cancelled or expired |
|
|
(26 |
) |
|
|
1.40 |
|
|
|
|
|
|
|
|
Outstanding at March 31, 2010 |
|
|
882 |
|
|
$ |
1.30 |
|
|
|
|
|
|
|
|
The Companys stock options activity for the nine months ended March 31, 2010 was as follows:
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Weighted Average |
|
|
|
(in thousands) |
|
|
Exercise Price |
|
Outstanding at December 31, 2009 |
|
|
1,125 |
|
|
$ |
2.27 |
|
|
|
|
|
|
|
|
Granted |
|
|
|
|
|
|
|
|
Exercised |
|
|
(174 |
) |
|
|
0.43 |
|
Cancelled or expired |
|
|
(69 |
) |
|
|
19.42 |
|
|
|
|
|
|
|
|
Outstanding at March 31, 2010 |
|
|
882 |
|
|
$ |
1.30 |
|
|
|
|
|
|
|
|
Restricted Stock
At March 31, 2010 and 2009, there was $2.6 million and $0.2 million of unrecognized compensation
costs related to restricted stock, respectively, which is expected to be recognized over a weighted
average period of 2.4 years.
The Companys restricted stock activity for the three months ended March 31, 2010 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
Average |
|
|
|
Shares |
|
|
Grant-Date |
|
|
|
(in thousands) |
|
|
Fair Value |
|
Non-vested at December 31, 2009 |
|
|
2,629 |
|
|
$ |
1.20 |
|
|
|
|
|
|
|
|
Granted |
|
|
|
|
|
|
|
|
Vested |
|
|
(12 |
) |
|
|
0.45 |
|
Cancelled or expired |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-vested at March 31, 2010 |
|
|
2,617 |
|
|
$ |
1.20 |
|
|
|
|
|
|
|
|
10
The Companys restricted stock activity for the nine months ended March 31, 2010 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
Average |
|
|
|
Shares |
|
|
Grant-Date |
|
|
|
(in thousands) |
|
|
Fair Value |
|
Non-vested at June 30, 2009 |
|
|
243 |
|
|
$ |
0.52 |
|
|
|
|
|
|
|
|
Granted |
|
|
2,406 |
|
|
|
1.27 |
|
Vested |
|
|
(12 |
) |
|
|
0.45 |
|
Cancelled or expired |
|
|
(20 |
) |
|
|
0.70 |
|
|
|
|
|
|
|
|
Non-vested at March 31, 2010 |
|
|
2,617 |
|
|
$ |
1.20 |
|
|
|
|
|
|
|
|
Restricted Stock 1st Detect
At March 31, 2010, there was $0.2 million of unrecognized compensation costs related to restricted
stock and warrants, which is expected to be recognized over a weighted average period of 1.8 years.
1st Detect restricted stock activity for the three months ended March 31, 2010 was as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
Grant-Date |
|
|
|
Shares |
|
|
Fair Value |
|
Non-vested at December 31, 2009 |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
|
|
Granted |
|
|
1,180 |
|
|
|
212.00 |
|
Vested |
|
|
|
|
|
|
|
|
Cancelled or expired |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-vested at March 31, 2010 |
|
|
1,180 |
|
|
$ |
212.00 |
|
|
|
|
|
|
|
|
Restricted Stock Astrogenetix
At March 31, 2010, there was $0.3 million of unrecognized compensation costs related to restricted
stock and warrants, which is expected to be recognized over a weighted average period of 1.8 years.
Astrogenetix restricted stock activity for the three months ended March 31, 2010 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
Grant-Date |
|
|
|
Shares |
|
|
Fair Value |
|
Non-vested at December 31, 2009 |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
|
|
Granted |
|
|
1,950 |
|
|
|
167.00 |
|
Vested |
|
|
|
|
|
|
|
|
Cancelled or expired |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-vested at March 31, 2010 |
|
|
1,950 |
|
|
$ |
167.00 |
|
|
|
|
|
|
|
|
11
11. Early Termination of Cost Plus Award Fee Contract
In May 2008, the Company received a letter from ARES Corporation (ARES) notifying us of ARESs
intent to terminate the Cost Plus Award Fee Subcontract No. SGS-0311403.00. The provision referred
to in ARESs correspondence provides for termination for convenience. The Company has
consistently received excellent reviews for its performance under the Subcontract and has earned
near maximum award fees. Previously, 45 employees of the Company were engaged under the
Subcontract, which resulted in no revenue for the current fiscal quarter.
The Company and ARES have not resolved certain issues relative to the early termination of the
Subcontract, including, but not limited to, a receivable from ARES under this contract totaling
$1.5 million. The Company is evaluating its contractual rights and other options with respect to
ARESs claimed termination of the Subcontract, including ARESs obligations with respect to such
claimed termination.
12. Purchase of Common Stock and Convertible Notes
Common stock or senior convertible notes payable repurchases under the Companys securities
repurchase program may be made from time-to-time, in the open market, through block trades or
otherwise in accordance with applicable regulations of the Securities and Exchange Commission.
Depending on market conditions and other factors, these purchases may be commenced or suspended at
any time or from time-to-time without prior notice. Additionally, the timing of such transactions
will depend on other corporate strategies and will be at the discretion of the management of the
Company.
In March 2009, the Company repurchased 300,000 shares of Common Stock at a price of $0.40 per
share, pursuant to the securities repurchase program. As of March 31, 2010, we had repurchased
311,660 shares of common stock at a cost of $0.2 million, which represents an average cost of $0.76
per share, and $1.1 million of senior convertible notes payable. As a result, the Company is
authorized to repurchase an additional $5.7 million of securities under this program.
Repurchase of Outstanding Notes
On October 31, 2008, the Company purchased $1,750,000 principal amount of its outstanding 5.5%
convertible notes due October 2010 from Curtiswood Capital LLC. Mr. R. Scott Nieboer, a director of
the Company until his resignation on September 30, 2009, was a beneficial owner of the repurchased
securities. The repurchased notes were acquired at an established market price on the day of trade
and will be retired by the Company. The Company recognized a gain of $0.7 million on the
transaction in the three months ended December 31, 2008.
13. Strategic Financial and Business Alternatives
In September 2009, the Company announced that the Board of Directors has engaged investment banking
firm Lazard Ltd. to advise the Company in exploring strategic financial and business alternatives
to enhance shareholder value. The range of alternatives which may be considered could include
strategic acquisitions, a sale of some or all of the companys assets or a variety of other
possible transactions. There can be no assurance regarding the timing of or whether the Company
will elect to pursue any of the strategic alternatives it may consider, that shareholders will
favor any proposed transaction, or that any such alternatives will result in changes to the
Companys plans or will be consummated.
14. Board of Director Resignation
On September 30, 2009, R. Scott Nieboer resigned from the Astrotech Board of Directors and the Audit
Committee of the Board of Directors. Mr. Nieboers decision to resign is not a result of a
disagreement with the Company related to the Companys operations, policies or practices. In
October 2009, the Board of Directors appointed current director Sha-Chelle Manning to fill the
vacancy on the Audit Committee.
15. Related Party Transactions
James D. Royston
In
December 2008, the Company entered into a seven month, renewable lease agreement with Mr.
Royston, President of Astrotech, to lease a house located in Melbourne, Florida to be used by
employees of the Company while conducting business on behalf of the Company. The lease provides for
monthly rental payments of $2,900 to Mr. Royston with expenses of utilities and consumables to be
paid by the Company. The lease was terminated by the Company in September 2009 and subsequently,
reinstated during October 2009.
12
Director Compensation
In August 2009, the Board of Directors granted 525,000 total restricted shares valued at $0.6
million to directors from the 2008 Stock Incentive Plan. The restricted shares vest 33.33% a year
for three years and expire upon termination. Compensation expense of $0.1 million was recorded in
the nine months ended March 31, 2010 for these awards.
Executive Compensation
On January 19, 2010, an independent committee of the Board of Directors of 1st Detect,
a subsidiary of the Astrotech Corporation (the Company), approved a grant of
restricted stock and warrants to certain officers, directors and employees of 1st Detect pursuant
to restricted stock agreements and stock purchase warrants between 1st Detect and each such
individual.
The awards will vest as follows, subject to earlier vesting upon the grantees death or disability
or in the event of a change of control of the Company: 50% on the first anniversary of the grant
date and 50% on the second anniversary of the grant date. The restricted stock agreements and stock
purchase warrants provide for forfeiture of unvested stock if the recipient is terminated or
voluntarily ceases to perform services for 1st Detect, immediate vesting upon a change of control,
and restrictions on and requirements as to transfer. The stock purchase warrants have an exercise
price equal to the fair market value of 1st Detects common stock on the date of grant as
determined by an independent valuation firm.
The number of shares and warrants underlying each award to a named executive officer is as follows:
Thomas B. Pickens III: 300 shares, 680 warrants; John Porter: 200 shares, 180 warrants. If all of
the shares issued pursuant to the restricted stock agreements vest and all of the stock purchase
warrants are exercised, then Thomas B. Pickens III would hold 9.8%, John Porter would hold 3.8% and
the Company would hold 70% of the outstanding shares of 1st Detect based on the number of
fully-diluted shares as of the date of the grants.
On
January 19, 2010, an independent committee of the Board of
Directors of Astrogenetix,
a subsidiary of the Company, approved a grant of restricted stock and warrants to
certain officers, directors and employees of Astrogenetix pursuant to restricted stock agreements
and stock purchase warrants between Astrogenetix and each such individual.
The awards will vest as follows, subject to earlier vesting upon the grantees death or disability
or in the event of a change of control of the Company: 50% on the first anniversary of the grant
date and 50% on the second anniversary of the grant date. The restricted stock agreements and stock
purchase warrants provide for forfeiture of unvested stock if the recipient is terminated or
voluntarily ceases to perform services for Astrogenetix, immediate vesting upon a change of
control, and restrictions on and requirements as to transfer. The stock purchase warrants have an
exercise price equal to the fair market value of Astrogenetixs common stock on the date of grant
as determined by an independent valuation firm.
The number of shares and warrants underlying each award to a named executive officer is as follows:
Thomas B. Pickens III: 500 shares, 1,000 warrants; John Porter: 400 shares, 800 warrants; James D.
Royston: 300 shares. If all of the shares issued pursuant to the restricted stock agreements vest
and all of the stock purchase warrants are exercised, then Thomas B. Pickens III would hold 16%,
John Porter would hold 13%, James D. Royston would hold 3% and the Company would hold 62% of the
outstanding shares of Astrogenetix based on the number of fully-diluted shares as of the date of
the grants.
The restricted stock issuances to certain officers and directors
described above are a component of the noncontrolling interest, as described in Note 3.
16. Subsequent Events
In March 2010, 1st Detect received notification that it was the recipient of a $1.8 million
investment from the Texas Emerging Technology Fund (TETF). In April 2010, the first half of the
investment, $0.9 million, was received by 1st Detect. The investment is being used to fund the
development and marketing of the Miniature Chemical Detector, a portable mass spectrometer which is
designed to serve the security, healthcare and industrial markets.
13
FORWARD-LOOKING STATEMENTS
This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other
than statements of historical fact are forward-looking statements for purposes of federal and
state securities laws. Forward-looking statements may include the words may, will, plans,
believes, estimates, expects, intends and other similar expressions. Such statements are
subject to risks and uncertainties that could cause our actual results to differ materially from
those projected in the statements. Such risks and uncertainties include, but are not limited to:
|
|
The effect of economic conditions in the U.S. or other space faring nations that could impact our
ability to access space and support or gain customers; |
|
|
|
Uncertainty about, and our ability to raise sufficient capital to meet our long and short-term
liquidity requirements; |
|
|
|
Our ability to successfully pursue our business plan; |
|
|
|
Whether we will fully realize the economic benefits under our NASA and other customer contracts; |
|
|
|
Continued availability and use of the U.S. Space Shuttle and the International Space Station; |
|
|
|
Technological difficulties and potential legal claims arising from any technological difficulties; |
|
|
|
Product demand and market acceptance risks, including our ability to develop and sell products
and services to be used by the manned and unmanned space programs that replace the Space Shuttle
Program; |
|
|
|
Uncertainty in government funding and support for key space programs; |
|
|
|
The impact of competition on our ability to win new contracts; |
|
|
|
Uncertainty in securing reliable and consistent access to space; |
|
|
|
Delays in the timing of performance of other contracts; and |
|
|
|
Risks described in the
Risk Factors section of our 2009 Form 10-K (as amended)
and this Form 10-Q. |
Although we believe that the assumptions underlying our forward-looking statements are reasonable,
any of the assumptions could be inaccurate, and, therefore, we cannot assure you that the
forward-looking statements included in this Form 10-Q will prove to be accurate. In light of the
significant uncertainties inherent in our forward-looking statements, the inclusion of such
information should not be regarded as a representation by us or any other person that our
objectives and plans will be achieved. Some of these and other risks and uncertainties that could
cause actual results to differ materially from such forward-looking statements are more fully
described in the Risk Factors included in Part II Item 1A of this Report and Part I, Item 1A of our
2009 10-K (as amended) and elsewhere in this Form 10-Q or in the documents incorporated by
reference herein. Except as may be required by applicable law, we undertake no obligation to
publicly update or advise of any change in any forward-looking statement, whether as a result of
new information, future events or otherwise. In making these statements, we disclaim any obligation
to address or update each factor in future filings with the Securities and Exchange Commission
(SEC) or communications regarding our business or results, and we do not undertake to address how
any of these factors may have caused changes to discussions or information contained in previous
filings or communications. In addition, any of the matters discussed above may have affected our
past results and may affect future results, so that our actual results may differ materially from
those expressed in this Form 10-Q and in prior or subsequent communications.
14
|
|
|
ITEM 2. |
|
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS |
The following information should be read in conjunction with the unaudited condensed consolidated
financial statements and the accompanying notes included in Part I, Item 1 of this Report.
OVERVIEW
Astrotech was formed in 1984 to leverage the environment of space for commercial purposes. For the
last 25 years, the Company has remained a crucial player in space commerce activities. We have
supported the launch of 23 shuttle missions and more than 280 spacecraft, building space hardware
and processing facilities, and preparing and processing scientific research for microgravity.
We offer products and services in the following areas:
|
|
|
Facilities and support services necessary for the preparation of satellites and payloads for launch. |
|
|
|
|
End-to-End Mission Assurance: a turn-key approach to the total satellite lifecycle. |
|
|
|
|
Commercialization of space-based technologies into real-world applications. |
|
|
|
|
Expertise in qualifying hardware for spaceflight and the habitability and occupational challenges
of space. |
Our Business Units
Astrotech Space Operations (ASO)
ASO provides support for its government and commercial customers to successfully process complex
communication, Earth observation and deep space satellites in preparation for their launch on a
variety of launch vehicles. Processing activities include satellite ground transportation;
pre-launch hardware integration and testing; satellite encapsulation, fueling, launch pad delivery;
and communication linked launch control. Our ASO facilities can accommodate five meter class
satellites encompassing the majority of U.S. based satellite preparation services. In addition to
satellite processing, ASO offers engineering services capabilities that encompass the entire life
cycle of a satellite. ASO accounted for 100% of our consolidated revenues for the three and nine
months ended March 31, 2010. Revenue for our ASO business unit is generated from various
fixed-priced contracts with launch service providers in both the commercial and government markets.
The services and facilities we provide to our customers support the final assembly, checkout, and
countdown functions associated with preparing a spacecraft for launch. The revenue and cash flows
generated from our ASO operations are related to the number of spacecraft launches, which reflects
the growth in the satellite-based communications industries and the requirement to replace aging
satellites. Other factors that have impacted, and are expected to continue to impact earnings and
cash flows for this business include:
|
|
|
Our ability to control our capital expenditures, which primarily are limited to modifications to
accommodate payload processing for new launch vehicles, upgrading communications infrastructure and
other building improvements. |
|
|
|
|
The continuing limited availability of competing facilities at the major domestic launch sites that can
offer comparable services, leading to an increase in government use of our services. |
|
|
|
|
Our ability to complete customer specified facility modifications within budgeted costs and time
commitments. |
|
|
|
|
Our ability to control and reduce costs in order to maximize profitability of our fixed-priced contracts. |
15
Spacetech
Our other business unit is an incubator intended to commercialize space-industry technologies into
commercial applications to be sold to consumers and industry. The 1st Detect
Miniature Chemical Detector, Astrogenetix microgravity processing platform and the AirWard
hazardous cargo containers are all initiatives developed under our Spacetech business unit. The
1st
Detect Miniature Chemical Detector, which is in development, is a low power, portable chemical detection
device intended to be utilized for a variety of applications. 1st Detect has been awarded a
Developmental Testing and Evaluation designation from the U.S. Department of Homeland Security as a
promising anti-terrorism technology, is the recipient of a Phase I award from the U.S. Armys
Chemical and Biological Defense (CBD) Small Business Innovation Research (SBIR) Program and
has received a $1.8 million investment commitment from the Texas Emerging Technology Fund. Astrogenetix
is performing drug discovery in microgravity as part of the National Lab Pathfinder Missions
designed by NASA. Astrognetix has identified a vaccine candidate for Salmonella and is
currently testing Methicilin Resistant Staphylococcous Aureous (MRSA).
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The discussion and analysis of our financial condition and results of operations are based upon our
unaudited condensed consolidated financial statements, which have been prepared in accordance with
United States generally accepted accounting principles for interim financial statements. The
preparation of these financial statements requires us to make estimates and judgments that affect
the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of
contingent assets and liabilities. We base our estimates on historical experience and on various
other assumptions that are believed to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Estimates and assumptions are reviewed periodically.
Actual results may differ from these estimates under different assumptions or conditions.
Management believes there have been no significant changes during the nine months ended March 31,
2010 to the items that we disclosed as our critical accounting policies and estimates in
Managements Discussion and Analysis of Financial Condition and Results of Operations in the 2009
10-K (as amended).
RESULTS OF OPERATIONS
Three months ended March 31, 2010 compared to three months ended March 31, 2009:
Selected consolidated financial data for the three months ended March 31, 2010 and 2009 is as
follows (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2010 |
|
|
2009 |
|
Revenue |
|
$ |
6,647 |
|
|
$ |
11,849 |
|
Gross profit |
|
|
3,287 |
|
|
|
7,024 |
|
|
|
|
|
|
|
|
Gross margin |
|
|
49 |
% |
|
|
59 |
% |
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
3,170 |
|
|
|
2,671 |
|
Research and development |
|
|
1,117 |
|
|
|
553 |
|
|
|
|
|
|
|
|
Operating expenses |
|
|
4,287 |
|
|
|
3,224 |
|
|
|
|
|
|
|
|
Interest and other expense, net |
|
|
(26 |
) |
|
|
(105 |
) |
Income tax expense |
|
|
53 |
|
|
|
(93 |
) |
|
|
|
|
|
|
|
Consolidated net income (loss) |
|
|
(973 |
) |
|
|
3,602 |
|
Less: Net loss attributable to noncontrolling interest |
|
|
(326 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Astrotech Corporation |
|
$ |
(647 |
) |
|
$ |
3,602 |
|
|
|
|
|
|
|
|
16
Revenue. Total revenue decreased to $6.6 million for the three months ended March 31, 2010,
from $11.8 million for the comparable period in fiscal 2009. The decrease was primarily
attributable to a decreased launch schedule at ASO. Additionally, the three months ended March 31,
2009 includes revenue earned constructing our newest 5-meter high bay at Vandenberg Air Force Base.
That project was complete in first quarter of fiscal year 2010.
Gross Profit. Gross profit decreased to $3.3 million for the three months ended March 31, 2010,
from $7.0 million for the comparable period in fiscal 2009. The gross margin decreased to 49% for
the three months ended March 31, 2010 as compared with 59% for the comparable period in fiscal
2009. The decrease in gross profit was attributable to a decrease in satellite payload processing
at ASO and the completion of the payload processing facility at Vandenberg Air Force Base during
the first quarter of fiscal year 2010.
Selling, General and Administrative Expense. Selling, general and administrative expense increased
to $3.2 million for the three months ended March 31, 2010 from $2.7 million for the comparable
period in fiscal 2009. The increase was primarily attributable to increased employee incentive
compensation expense, an increase in business development personnel and higher outside consulting
fees. As a percentage of revenue, selling, general and administrative expenses increased to 48% for
the three months ended March 31, 2010, on lower revenue, as compared to 23% for the comparable
period in fiscal 2009.
Research and Development Expense. Research and development expense increased to $1.1 million for
the three months ended March 31, 2010 from $0.6 million for the comparable period in fiscal 2009.
As a percentage of revenue, research and development expense increased to 17% for the three months
ended March 31, 2010 as compared with 5% for the comparable period in fiscal 2009. The increase in
expense was the result of our investments in the development of the 1st Detect mini-mass
spectrometer and the Astrogenetix microgravity processing platform.
Interest and Other Expense, net. Interest and other expense, net, decreased to $0.03 million for
the three months ended March 31, 2010, as compared with $0.1 million for the comparable period in
fiscal 2009. Interest expense on the term loan and senior convertible notes was offset by higher
interest income from our short-term cash investment in the period ended March 31, 2010 due to the
larger cash balance available for investment.
Nine months ended March 31, 2010 compared to nine months ended March 31, 2009:
Selected consolidated financial data for the nine months ended March 31, 2010 and 2009 is as
follows (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
March, |
|
|
|
2010 |
|
|
2009 |
|
Revenue |
|
$ |
22,489 |
|
|
$ |
21,608 |
|
Gross profit |
|
|
13,527 |
|
|
|
10,015 |
|
|
|
|
|
|
|
|
Gross
margin |
|
|
60 |
% |
|
|
46 |
% |
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
9,515 |
|
|
|
6,520 |
|
Research and development |
|
|
2,119 |
|
|
|
1,636 |
|
|
|
|
|
|
|
|
Operating expenses |
|
|
11,634 |
|
|
|
8,156 |
|
Gain on notes repurchased |
|
|
|
|
|
|
665 |
|
Interest and other expense, net |
|
|
(366 |
) |
|
|
(329 |
) |
Income tax expense |
|
|
(22 |
) |
|
|
(93 |
) |
|
|
|
|
|
|
|
Consolidated net income |
|
|
1,505 |
|
|
|
2,102 |
|
Less: Net loss attributable to noncontrolling interest |
|
|
(326 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to Astrotech Corporation |
|
$ |
1,831 |
|
|
$ |
2,102 |
|
|
|
|
|
|
|
|
17
Revenue. Total revenue increased to $22.5 million for the nine months ended March 31, 2010,
from $21.6 million for the comparable period in fiscal 2009. The increase was primarily
attributable to an increased launch schedule during the first two quarters at ASO and additional
revenue associated with the completion of the construction for our payload processing facility at
Vandenberg Air Force Base.
Gross Profit. Gross profit increased to $13.5 million for the nine months ended March 31, 2010,
from $10.0 million for the comparable period in fiscal 2009. The gross margin increased to 60% the
nine months ended March 31, 2010, up from 46% for the comparable period in fiscal 2009. The
increase in gross profit was primarily attributable to an increase in overall payload processing
volume.
Selling, General and Administrative Expense. Selling, general and administrative expense increased
to $9.5 million for the nine months ended March 31, 2010, up from $6.5 million for the comparable
period in fiscal 2009. The increase was primarily attributable to increased employee incentive
compensation expense, for the hiring of additional business development personnel, increased
outside fees, additional legal expenses and an increase in insurance premiums. As a percentage of
revenue, selling, general and administrative expenses increased to 42% the nine months ended March
31, 2010 as compared to 30% for the comparable period in fiscal 2009.
Research and Development Expense. Research and development expense increased to $2.1 million for
the nine months ended March 31, 2010, from $1.6 million for the comparable period in fiscal 2009.
As a percentage of revenue, research and development expense increased to 9% the nine months ended
March 31, 2010 as compared with 8% for the comparable period in fiscal 2009. The increase in
expense was the result of our investments in the development of the 1st Detect mini-mass
spectrometer and the Astrogenetix microgravity processing platform.
Gain
on Notes Repurchased. In the nine months ended March 31, 2009, there
was a gain of $0.7 million on the repurchase of $1.8
million of our senior convertible notes.
Interest and Other Expense, net. Interest and other expense, net, increased to $0.4 million for the
nine months ended March 31, 2010 as compared to $0.3 million for the comparable period in fiscal
2009. Interest expense relates to interest on the senior convertible notes and the term loan,
offset by interest income primarily from our money market. Also included in other expense for the
nine months ended March 31, 2010 is the write-off of $0.2 million of aerospace metals.
LIQUIDITY AND CAPITAL RESOURCES
As of March 31, 2010, we had cash and cash equivalents of $6.3 million and our working capital was
approximately $3.5 million. As of March 31, 2009, we had cash and restricted cash-on-hand of
$4.5 million and our working capital was approximately $3.3 million.
The following is a summary of the change in our cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
March 31, |
|
|
|
2010 |
|
|
2009 |
|
Net cash provided by (used in) operating activities |
|
$ |
2,995 |
|
|
$ |
3 |
|
Net cash used in investing activities |
|
|
(1,347 |
) |
|
|
(538 |
) |
Net cash used in financing activities |
|
|
(125 |
) |
|
|
(855 |
) |
|
|
|
|
|
|
|
Net change in cash and cash equivalents |
|
$ |
1,523 |
|
|
$ |
(1,390 |
) |
|
|
|
|
|
|
|
18
Operating Activities
During the
nine months ended March 31, 2010, net cash provided by operations was $3.0 million
and included net income of $2.3 million. During the nine months ended March 31, 2009, net cash
provided by operations was $3,000 and included net income of $2.1 million.
Changes in assets and liabilities affecting our operating cash flows for the nine months ended
March 31, 2010 are as follows:
Assets. Accounts receivable decreased $4.0 million during the nine months ended March 31, 2010.
This was a result of the timing of payments received by the Company, including the collection of
amounts due on the facility construction at Vandenberg Air Force Base.
Liabilities. Cash provided by operating activities was used primarily to reduce accounts payable,
which decreased $2.3 million in the nine months ended March 31, 2010. Deferred revenue
decreased $2.4 million in the nine months ended March 31, 2010. Deferred revenue represents amounts
collected from customers for projects, products, or services expected to be provided at a future
date. The change is a result of a timing difference between cash collections on payload processing
customer contracts and amounts earned as revenue.
Investing Activities
In the nine months ended March 31, 2010, cash used in investing activities was $1.3 million, up
from $0.5 million cash used in the comparable period in fiscal 2009. The $1.3 million use of cash
in the nine months ended March 31, 2010, was attributable to the completion of construction on our
administrative building at Vandenberg Air Force Base.
Financing Activities
Cash used in financing activities for the nine months ended March 31, 2010, was $0.1 million, down
from $0.9 million for the comparable period in fiscal 2009. During the nine months ended March 31,
2010, the Company made interest payment on our term loan of $0.2 million. During the nine months
ended March 31, 2009, the Company purchased $1.8 million in principal amount of its outstanding
senior convertible notes offset by a gain of $0.7 million, made interest payments on our term loan
of $0.2 million, repurchased treasury stock of $0.1 million and had proceeds of $0.6 million from
our revolving credit facility.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2010 |
|
|
June 30, 2009 |
|
|
|
Carrying |
|
|
Fair |
|
|
Carrying |
|
|
Fair |
|
|
|
Amount |
|
|
Value |
|
|
Amount |
|
|
Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term loan payable |
|
$ |
3,415 |
|
|
$ |
3,415 |
|
|
$ |
3,591 |
|
|
$ |
3,591 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior convertible notes payable - 5.5% |
|
$ |
5,111 |
|
|
$ |
2,658 |
|
|
$ |
5,111 |
|
|
$ |
2,650 |
|
Maturity of Outstanding Debt
Over the next year, the $5.1 million of senior convertible notes and the $3.4 million term loan
will become due. The Company believes that we will have sufficient working capital to repay the
senior convertible notes at maturity in October 2010. The term loan is expected to be replaced
with a new debt facility. There can be no assurance that additional
or replacement debt financing will be available in
the future or that we will have sufficient cash flow in order to make
these repayments.
19
Off-Balance Sheet Arrangements
We do not have any significant off-balance sheet arrangements that have, or are reasonably likely
to have, a current or future material effect on our financial condition, revenues or expenses,
results of operations, liquidity, capital expenditures or capital resources.
|
|
|
ITEM 3. |
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
We have no material changes to the disclosure made on this matter in our 2009 10-K (as amended).
|
|
|
ITEM 4. |
|
CONTROLS AND PROCEDURES |
(a) Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the
Securities Exchange Act of 1934 (Exchange Act), which are designed to ensure that information
required to be disclosed by us in the reports that we file or submit under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the Securities
and Exchange Commissions rules and forms and that such information is accumulated and communicated
to our management, including our Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow timely decisions regarding required disclosure. We carried out an evaluation,
under the supervision and with the participation of our management, including our Chief Executive
Officer and Chief Financial Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures, as of the end of the period covered by this quarterly report.
Based on the evaluation and criteria of these disclosure controls and procedures, the Chief
Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
were effective.
(b) Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting identified in connection
with the evaluation required by Exchange Act Rule 13a-15(d) during the quarter ended March 31,
2010, that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.
PART II: OTHER INFORMATION
|
|
|
ITEM 1. |
|
LEGAL PROCEEDINGS |
Currently, the Company is not a party to any material pending legal proceedings, which in
managements opinion, would have a material adverse effect on our business, financial condition, or
results of operation.
Material
risks relating to our business and the ownership of our securities,
which are in addition to those described in Item 1-A of our 2009 10-K (as amended),
include the following:
The review of strategic alternatives may not enhance shareholder value
In September 2009, the Company announced that the Board of Directors has engaged investment banking
firm Lazard Ltd. to advise the Company in exploring strategic financial and business alternatives
to enhance shareholder value. The range of alternatives which may be considered could include
strategic acquisitions, a sale of some or all of the companys assets or a variety of other
possible transactions. There can be no assurance regarding the timing of or whether the Company
will elect to pursue any of the strategic alternatives it may consider, that shareholders will
favor any proposed transaction, or that any such alternatives will result in changes to the
Companys plans or will be consummated. In addition, in 2010, we have incurred significant costs in
order to evaluate these strategic alternatives. There can be no assurance that the costs incurred
will result in a transaction.
20
Our Spacetech business unit is in an early development stage. It has earned no revenues and it
is uncertain whether it will earn any revenues in the future or whether it will ultimately be
profitable.
Our Spacetech business unit is in an early development stage with no commercial sales and a limited
operating history. Its future operations are subject to all of the risks inherent in the
establishment of a new business enterprise including, but not limited to, risks related to capital
requirements, failure to establish business relationships and competitive disadvantages as against
larger and more established companies. The Spacetech business unit will require substantial amounts
of funding to develop, test and commercialize its products. If such funding comes in the form of
equity financing, such equity financing may involve substantial dilution to existing shareholders.
Even with funding, our product development program may not lead to commercial products, either
because our product candidates fail to be effective, are not attractive to the market or because we
lack the necessary financial or other resources or relationships to pursue our programs through
commercialization.
The Spacetech business unit can be expected to experience significant operating losses until it can
generate sufficient revenues to cover its operating costs. The Spacetech business unit currently
has no commercial products and there can be no assurance that the business will be able to develop,
manufacture or market any products in the future, that future revenues will be significant, that
any sales will be profitable or that the business will have sufficient funds available to complete
its marketing and development programs or to market any products which it may develop.
Any products and technologies developed and manufactured by our Spacetech business unit may require
regulatory approval prior to being made, marketed, sold and used. There can be no assurance that
regulatory approval of any products will be obtained.
The commercial success of the Spacetech business unit is expected to depend, in part, on obtaining
patent and other intellectual property protection for the technologies contained in any products it
develops. In addition, the Spacetech business unit may need to license intellectual property to
commercialize future products or avoid infringement of the intellectual property rights of others.
There can be no assurance that licenses will be available on acceptable terms and conditions, if at
all. The Spacetech business unit may suffer if any licenses terminate, if the licensors fail to
abide by the terms of the license or fail to prevent infringement by third parties, if the licensed
patents or other rights are found to be invalid or if the Spacetech business unit is unable to
enter into necessary licenses on acceptable terms. If the Spacetech business unit, or the third
parties from whom it licenses intellectual property, fail to obtain adequate patent or other
intellectual property protection for intellectual property covering its products, or if any
protection is reduced or eliminated, others could use the intellectual property covering the
products, resulting in harm to the competitive business position of the Spacetech business unit. In
addition, patent and other intellectual property protection may not provide the Spacetech business
unit with a competitive advantage against competitors that devise ways of making competitive
products without infringing any patents that the Spacetech business unit owns or has rights to.
Such competition could adversely affect the prices for any products or the market share of the
Spacetech business unit and could have a material adverse effect upon its results of operations and
financial condition.
|
|
|
ITEM 2. |
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
During the quarter ended March 31, 2010, we did not issue any unregistered securities or repurchase
any of our securities.
|
|
|
ITEM 3. |
|
DEFAULTS UPON SENIOR SECURITIES |
During the quarter ended March 31, 2010, we did not have any defaults upon our senior securities.
21
|
|
|
ITEM 4. |
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS |
Astrotech Corporation (the Company) held its Annual Meeting of Shareholders (the Annual
Meeting) on March 5, 2010, at the Companys headquarters located in Austin, Texas. Shareholders
representing 14,751,876 shares or 77.6% of the Companys outstanding shares of common stock were
present in person or by proxy at the Annual Meeting. The proposals below are described in detail in
the Companys proxy statement dated January 26, 2010.
Three proposals were included for voting:
|
1) |
|
Election of six directors to the Companys Board of Directors; |
Director Nominee:
Thomas B. Pickens III
Mark Adams
Lance W. Lord
John A. Olivia
William F. Readdy
Sha-Chelle Manning
|
2) |
|
Ratification of the appointment of PMB Helin Donovan, LLP as
independent registered public accountants for the Company; |
|
|
3) |
|
Approval of the Companys 2010 Stock Incentive Plan. |
Proposals 1 and 2 were approved; proposal 3 did not receive the necessary votes for approval.
|
|
|
ITEM 5. |
|
OTHER INFORMATION |
Not applicable.
22
The following exhibits are filed herewith:
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
10.1 |
|
|
Form of Restricted Stock Agreement 1st Detect Corporation |
|
|
|
|
|
|
10.2 |
|
|
Form of Stock Purchase Warrant 1st Detect Corporation |
|
|
|
|
|
|
10.3 |
|
|
Form of Restricted Stock Agreement Astrogenetix, Inc. |
|
|
|
|
|
|
10.4 |
|
|
Form of Stock Purchase Warrant Astrogenetix, Inc. |
|
|
|
|
|
|
31.1 |
|
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the
Securities Exchange Act of 1934. |
|
|
|
|
|
|
31.2 |
|
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the
Securities Exchange Act of 1934. |
|
|
|
|
|
|
32 |
|
|
Certification Pursuant to Rule 13a-14(b) of the Securities and Exchange Act of 1934. |
23
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
Astrotech Corporation
|
|
Date: May 17, 2010 |
/s/ Thomas B. Pickens, III
|
|
|
Thomas B. Pickens, III |
|
|
Chief Executive Officer |
|
|
|
|
|
/s/ John M. Porter
|
|
|
John M. Porter |
|
|
Senior Vice President and
Chief Financial Officer |
|
24